Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

Daichi Yamasoba¹, Yusuke Kosugi², Izumi Kimura², Shigeru Fujita², Keiya Uriu², Jumpei Ito², Kei Sato³; Genotype to Phenotype Japan (G2P-Japan) Consortium

Affiliations

¹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; School of Medicine, Kobe University, Kobe, Hyogo, Japan.
² Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
³ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; CREST, Kawaguchi, Saitama, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp.

PMID: 35690075
PMCID: PMC9179126
DOI: 10.1016/S1473-3099(22)00365-6

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

Daichi Yamasoba et al. Lancet Infect Dis. 2022 Jul.

. 2022 Jul;22(7):942-943.

doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.

Authors

Daichi Yamasoba¹, Yusuke Kosugi², Izumi Kimura², Shigeru Fujita², Keiya Uriu², Jumpei Ito², Kei Sato³; Genotype to Phenotype Japan (G2P-Japan) Consortium

Affiliations

¹ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; School of Medicine, Kobe University, Kobe, Hyogo, Japan.
² Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
³ Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; CREST, Kawaguchi, Saitama, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp.

PMID: 35690075
PMCID: PMC9179126
DOI: 10.1016/S1473-3099(22)00365-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. DY, YK, and IK contributed equally. This work was supported in part by the Japan Agency for Medical Research and Development (AMED) Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146 to KS, JP20fk0108413 to KS, and JP20fk0108451 to G2P-Japan Consortium and KS), the AMED Research Program on HIV/AIDS (JP22fk0410039 to KS), the Japan Science and Technology Agency CREST programme (JPMJCR20H4 to KS), the Japan Society for the Promotion of Science (JSPS) Fund for the Promotion of Joint International Research (Fostering Joint International Research; 18KK0447 to KS), the JSPS Core-to-Core Program JPJSCCA20190008 (A. Advanced Research Networks; to KS), the JSPS Research Fellow DC2 22J11578 (to KU), and The Tokyo Biochemical Research Foundation (to KS).

Comment in

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
Arora P, Kempf A, Nehlmeier I, Schulz SR, Cossmann A, Stankov MV, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M. Arora P, et al. Lancet Infect Dis. 2022 Aug;22(8):1117-1118. doi: 10.1016/S1473-3099(22)00422-4. Epub 2022 Jun 28. Lancet Infect Dis. 2022. PMID: 35777385 Free PMC article. No abstract available.
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
Hentzien M, Autran B, Piroth L, Yazdanpanah Y, Calmy A. Hentzien M, et al. Lancet Infect Dis. 2022 Sep;22(9):1278. doi: 10.1016/S1473-3099(22)00495-9. Epub 2022 Jul 18. Lancet Infect Dis. 2022. PMID: 35863364 Free PMC article. No abstract available.

References

1. Ferreira I, Kemp SA, Datir R, et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J Infect Dis. 2021;224:989–994. - PMC - PubMed
1. Kimura I, Kosugi Y, Wu J, et al. The SARS-CoV-2 lambda variant exhibits enhanced infectivity and immune resistance. Cell Rep. 2022;38 - PMC - PubMed
1. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022 doi: 10.1038/s41591-022-01792-5. published online March 23. - DOI - PubMed
1. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med. 2022;386:1475–1477. - PMC - PubMed
1. Case JB, Mackin S, Errico J, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 omicron lineage strains. bioRxiv. 2022 doi: 10.1101/2022.03.17.484787. published online March 18. (preprint). - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

Affiliations

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

Authors

Affiliations

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous